Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd
Company Profile
Business description
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, it has built a diversified product portfolio comprising several marketed products, such as Jilifen, Jijufen, Jiouting, Yinuojia, Guyoudao, etc., and has several product candidates under development, such as JY54, JY23, JY47, JY56, JY29-2, etc., targeting various indications. Geographically, the company generates maximum revenue from the Chinese Mainland, and the rest from other countries.
Contact
No. 23, Eighth Street, Baiyang Street
Qiantang District
Zhejiang Province
Hangzhou
CHNT: +86 57186910099
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,794
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
stocks
Why it’s not all bad news for Flight Centre following downgrade
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.20 | 1.20 | -0.01% |
| CAC 40 | 8,384.87 | 46.74 | -0.55% |
| DAX 40 | 24,671.22 | 323.61 | -1.29% |
| Dow JONES (US) | 51,876.11 | 44.51 | -0.09% |
| FTSE 100 | 10,508.02 | 21.87 | -0.21% |
| HKSE | 22,671.86 | 405.05 | -1.76% |
| NASDAQ | 25,297.62 | 60.99 | -0.24% |
| Nikkei 225 | 69,360.88 | 3,005.46 | -4.15% |
| NZX 50 Index | 13,495.24 | 2.19 | 0.02% |
| S&P 500 | 7,354.02 | 3.47 | -0.05% |
| S&P/ASX 200 | 8,764.20 | 0.20 | 0.00% |
| SSE Composite Index | 4,027.26 | 93.02 | -2.26% |